These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37011138)

  • 1. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.
    Hassanein T; McClain CJ; Vatsalya V; Stein LL; Flamm SL; Martin P; Cave MC; Mitchell M; Barton B; Nagy L; Szabo G; McCullough A; Dasarathy S; Shah J; Blevins C; Scott D; Krebs W; Brown JE; Lin W
    Am J Gastroenterol; 2024 Jan; 119(1):107-115. PubMed ID: 37011138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.
    Arab JP; Sehrawat TS; Simonetto DA; Verma VK; Feng D; Tang T; Dreyer K; Yan X; Daley WL; Sanyal A; Chalasani N; Radaeva S; Yang L; Vargas H; Ibacache M; Gao B; Gores GJ; Malhi H; Kamath PS; Shah VH
    Hepatology; 2020 Aug; 72(2):441-453. PubMed ID: 31774566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.
    Cho Y; Park YS; Kim HY; Kim W; Lee HJ; Kim DJ
    Trials; 2018 Dec; 19(1):696. PubMed ID: 30577864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.
    Trépo E; Goossens N; Fujiwara N; Song WM; Colaprico A; Marot A; Spahr L; Demetter P; Sempoux C; Im GY; Saldarriaga J; Gustot T; Devière J; Thung SN; Minsart C; Sersté T; Bontempi G; Abdelrahman K; Henrion J; Degré D; Lucidi V; Rubbia-Brandt L; Nair VD; Moreno C; Deltenre P; Hoshida Y; Franchimont D
    Gastroenterology; 2018 Mar; 154(4):965-975. PubMed ID: 29158192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial.
    Sharma P; Kumar A; Sharma BC; Sarin SK
    J Hepatol; 2009 Mar; 50(3):584-91. PubMed ID: 19155081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.
    Dasarathy S; Mitchell MC; Barton B; McClain CJ; Szabo G; Nagy LE; Radaeva S; McCullough AJ
    Contemp Clin Trials; 2020 Sep; 96():106094. PubMed ID: 32739495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis.
    Singh V; Keisham A; Bhalla A; Sharma N; Agarwal R; Sharma R; Singh A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1650-1656.e2. PubMed ID: 29391265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis.
    Tayek JA; Stolz AA; Nguyen DV; Fleischman MW; Donovan JA; Alcorn JM; Chao DC; Asghar A; Morgan TR;
    EClinicalMedicine; 2022 Dec; 54():101689. PubMed ID: 36267499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis.
    Lee BP; Samur S; Dalgic OO; Bethea ED; Lucey MR; Weinberg E; Hsu C; Rinella ME; Im GY; Fix OK; Therapondos G; Han H; Victor DW; Voigt MD; Eswaran S; Terrault NA; Chhatwal J
    Gastroenterology; 2019 Aug; 157(2):472-480.e5. PubMed ID: 30998988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases.
    Wang Y; Ren J; Ren S
    Am J Physiol Endocrinol Metab; 2024 May; 326(5):E577-E587. PubMed ID: 38381400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model of disease severity in alcoholic hepatitis and novel prognostic insights.
    Enciu VT; Ologeanu PM; Călin-Necula AM; Moldoveanu AC; Oprea-Călin G; Fierbinţeanu-Braticevici C
    Rom J Intern Med; 2024 Jun; 62(2):194-202. PubMed ID: 38180800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.
    Mitchell MC; Friedman LS; McClain CJ
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):5-12. PubMed ID: 27979049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort.
    Papastergiou V; Tsochatzis EA; Pieri G; Thalassinos E; Dhar A; Bruno S; Karatapanis S; Luong TV; O'Beirne J; Patch D; Thorburn D; Burroughs AK
    Aliment Pharmacol Ther; 2014 Apr; 39(7):721-32. PubMed ID: 24612165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study.
    Kasuga R; Chu PS; Taniki N; Yoshida A; Morikawa R; Tabuchi T; Noguchi F; Yamataka K; Nakadai Y; Kondo M; Ebinuma H; Kanai T; Nakamoto N
    Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.
    Louvet A; Labreuche J; Artru F; Boursier J; Kim DJ; O'Grady J; Trépo E; Nahon P; Ganne-Carrié N; Naveau S; Diaz E; Gustot T; Lassailly G; Cannesson-Leroy A; Canva-Delcambre V; Dharancy S; Park SH; Moreno C; Morgan TR; Duhamel A; Mathurin P
    Gastroenterology; 2015 Aug; 149(2):398-406.e8; quiz e16-7. PubMed ID: 25935634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.
    Arab JP; Díaz LA; Baeza N; Idalsoaga F; Fuentes-López E; Arnold J; Ramírez CA; Morales-Arraez D; Ventura-Cots M; Alvarado-Tapias E; Zhang W; Clark V; Simonetto D; Ahn JC; Buryska S; Mehta TI; Stefanescu H; Horhat A; Bumbu A; Dunn W; Attar B; Agrawal R; Haque ZS; Majeed M; Cabezas J; García-Carrera I; Parker R; Cuyàs B; Poca M; Soriano G; Sarin SK; Maiwall R; Jalal PK; Abdulsada S; Higuera-de la Tijera MF; Kulkarni AV; Rao PN; Guerra Salazar P; Skladaný L; Bystrianska N; Prado V; Clemente-Sanchez A; Rincón D; Haider T; Chacko KR; Cairo F; de Sousa Coelho M; Romero GA; Pollarsky FD; Restrepo JC; Castro-Sanchez S; Toro LG; Yaquich P; Mendizabal M; Garrido ML; Narvaez A; Bessone F; Marcelo JS; Piombino D; Dirchwolf M; Arancibia JP; Altamirano J; Kim W; Araujo RC; Duarte-Rojo A; Vargas V; Rautou PE; Issoufaly T; Zamarripa F; Torre A; Lucey MR; Mathurin P; Louvet A; García-Tsao G; González JA; Verna E; Brown RS; Roblero JP; Abraldes JG; Arrese M; Shah VH; Kamath PS; Singal AK; Bataller R
    J Hepatol; 2021 Nov; 75(5):1026-1033. PubMed ID: 34166722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).
    Jiménez C; Ventura-Cots M; Sala M; Calafat M; Garcia-Retortillo M; Cirera I; Cañete N; Soriano G; Poca M; Simón-Talero M; Altamirano J; Lucey M; Garcia-Tsao G; Brown RS; Schwabe RF; Verna EC; Schnabl B; Bosques-Padilla F; Mathurin P; Caballería J; Louvet A; Shawcross DL; Abraldes JG; Genescà J; Bataller R; Vargas V
    Liver Int; 2022 May; 42(5):1109-1120. PubMed ID: 35220659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis.
    McLean Diaz P; Vannier A; Joshi AD; Mahle RE; Przybyszewski EM; Corey K; Chung RT; Luther J; Goodman RP; Schaefer EAK
    Clin Transl Gastroenterol; 2023 Jun; 14(6):e00585. PubMed ID: 36972232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.